Grace Therapeutics (NASDAQ:GRCE – Get Free Report) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.
Other research analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Grace Therapeutics in a report on Friday, July 17th. Wall Street Zen lowered Grace Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Craig Hallum set a $4.00 target price on Grace Therapeutics in a report on Friday, April 24th. Finally, TD Cowen dropped their target price on Grace Therapeutics from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, April 24th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Grace Therapeutics currently has an average rating of “Hold” and a consensus price target of $6.00.
View Our Latest Report on GRCE
Grace Therapeutics Price Performance
Grace Therapeutics (NASDAQ:GRCE – Get Free Report) last posted its quarterly earnings results on Thursday, June 18th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.17. On average, equities analysts expect that Grace Therapeutics will post -0.8 EPS for the current year.
Institutional Trading of Grace Therapeutics
A number of large investors have recently added to or reduced their stakes in the stock. Stratos Wealth Partners LTD. purchased a new position in Grace Therapeutics in the fourth quarter valued at about $39,000. Kestra Private Wealth Services LLC bought a new stake in shares of Grace Therapeutics in the 1st quarter worth approximately $60,000. SeaCrest Wealth Management LLC purchased a new position in Grace Therapeutics in the third quarter valued at approximately $42,000. XTX Topco Ltd purchased a new position in Grace Therapeutics in the fourth quarter valued at approximately $106,000. Finally, Pale Fire Capital SE bought a new position in Grace Therapeutics during the first quarter valued at $175,000. Hedge funds and other institutional investors own 6.08% of the company’s stock.
About Grace Therapeutics
Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.
The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.
Featured Articles
- Five stocks we like better than Grace Therapeutics
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Grace Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grace Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
